KALA BIO Completes $10 Million Funding Round to Advance Rare Eye Disease Therapies
Key Insights
KALA BIO (search) successfully closed a $10 million registered direct offering on December 5, 2025, selling 10 million shares at $1.00 per share to fund operations and debt repayment.
The clinical-stage biopharmaceutical company focuses on developing innovative therapies for rare and severe eye diseases using its proprietary mesenchymal stem cell secretome (search) platform.
KALA's lead product candidate KPI-012 has received FDA Orphan Drug and Fast Track designations for treating persistent corneal epithelial defect (search), a rare corneal healing disorder.
KALA BIO (search), Inc. (NASDAQ:KALA) successfully completed a $10 million registered direct offering on December 5, 2025, providing crucial funding to advance its pipeline of innovative therapies for rare and severe eye diseases. The Arlington, Massachusetts-based clinical-stage biopharmaceutical company sold 10 million shares of common stock at $1.00 per share in the at-the-market offering under Nasdaq rules.
H.C. Wainwright & Co. (search) served as the exclusive placement agent for the transaction, which generated approximately $10 million in gross proceeds before deducting placement agent fees and other offering expenses. The company plans to use the net proceeds to repay certain indebtedness and support general corporate purposes as it continues developing its proprietary therapeutic platform.
Proprietary MSC-S Platform Technology
KALA's biologics-based investigational therapies utilize the company's proprietary mesenchymal stem cell secretome (search) (MSC-S) platform, which represents a novel approach to treating ocular diseases. This platform harnesses the therapeutic potential of factors naturally secreted by mesenchymal stem cells to address conditions with significant unmet medical needs.
The company's lead product candidate, KPI-012, is a human MSC-S containing numerous human-derived biofactors, including growth factors, protease inhibitors, matrix proteins, and neurotrophic factors. This comprehensive composition of bioactive molecules positions KPI-012 as a potentially transformative treatment for challenging ocular conditions.
FDA Recognition for Rare Disease Treatment
KPI-012 has received both Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for the treatment of persistent corneal epithelial defect (search) (PCED (search)), a rare disease characterized by impaired corneal healing. These regulatory designations underscore the significant unmet medical need in this patient population and provide KALA with important development and commercial advantages.
The Orphan Drug designation provides market exclusivity incentives and fee reductions, while the Fast Track designation facilitates more frequent FDA meetings and potentially accelerated review timelines. These regulatory pathways reflect the FDA's recognition of PCED (search) as a serious condition requiring innovative therapeutic approaches.
Strategic Funding for Continued Development
The completed offering was conducted under a shelf registration statement filed with the Securities and Exchange Commission on March 3, 2023, and declared effective on May 11, 2023. This financing structure provides KALA with flexibility to access capital markets as needed to support its clinical development programs and operational requirements.
The funding comes at a critical time for KALA as the company advances its MSC-S platform and prepares for potential clinical milestones with KPI-012. The company's focus on rare and severe eye diseases represents a strategic approach to addressing conditions with limited treatment options and significant patient impact.